Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
7.75
+0.19 (2.51%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 26, with a low estimate of 17 and a high estimate of 47. The average target predicts an increase of 235.48% from the current stock price of 7.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +183.87% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +506.45% | Mar 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +209.68% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +183.87% | Mar 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $24 | Strong Buy | Maintains | $24 | +209.68% | Feb 19, 2025 |
Financial Forecast
Revenue This Year
39.27M
from 36.56M
Increased by 7.43%
Revenue Next Year
30.33M
from 39.27M
Decreased by -22.77%
EPS This Year
-2.07
from -1.65
EPS Next Year
-2.54
from -2.07
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.1M | 73.5M | 163.8M | ||
| Avg | 39.3M | 30.3M | 51.5M | ||
| Low | 5.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 135.5% | 87.2% | 440.1% | ||
| Avg | 7.4% | -22.8% | 69.8% | ||
| Low | -83.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.98 | -0.67 | -0.18 | ||
| Avg | -2.07 | -2.54 | -2.21 | ||
| Low | -2.63 | -3.53 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.